Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
Information source: Astellas Pharma Inc
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Candidiasis, Oral
Intervention: Micafungin (Drug); Fluconazole (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Astellas Pharma Inc Official(s) and/or principal investigator(s): Use central contact, Study Director, Affiliation: Astellas Pharma US, Inc.
Summary
To determine the efficacy and safety of IV Micafungin versus IV Fluconazole in the treatment
of patients with Esophageal Candidiasis
Clinical Details
Official title: A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study
Primary outcome: Endoscopic cure rate, defined as a mucosal grade of zero at the end of the therapy
Secondary outcome: Clinical response at end of therapy of cleared or improvedMucosal response at end of therapy of cleared or improved
Eligibility
Minimum age: 16 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of esophageal candidiasis confirmed by endoscopy
- Negative pregnancy test in females of childbearing potential
Exclusion Criteria:
- Pregnant or nursing
- Evidence of liver disease
- Presence of another active opportunistic fungal infection and/or receiving acute
systemic therapy for an opportunistic fungal infection
- Concomitant esophagitis caused by herpes simplex virus or cytomegalovirus
- Receipt of an oral or topical antifungal agent within 48 hours or a systemic agent
within 72 hours of first dose of study drug
- Non-responsive to therapy in any prior systemic antifungal clinical trail
- History of > 2 episodes of esophageal candidiasis requiring systemic antifungal
therapy
- History of anaphylaxis attributed to azole compounds or echinocandin class of
antifungals
Locations and Contacts
2 Sites, Curitiba, Brazil
2 Sites, Campinas, Brazil
5 Sites, Belo Horizonte, Brazil
Nova Iguacu, Brazil
4 Sites, Rio de Janeiro, Brazil
Porto Alegre, Brazil
Parquelandia - Fortaleza, Brazil
8 Sites, Sao Paulo, Brazil
Boqueirao - Santos, Brazil
Maruipe Victoria, Brazil
Goiania, Brazil
2 Sites, Salvador, Brazil
Barretos, Brazil
Sao Jose do Rio Preto, Brazil
Quinta - Natal, Brazil
Abadia Uberaba, Brazil
4 Sites, Lima, Peru
3 Sites, Pretoria, South Africa
2 Sites, Durban, South Africa
Centurion, South Africa
Paarl, South Africa
Johannesburg, South Africa
Arcadia-Pretoria, South Africa
Pretoria West, South Africa
Cape Town, South Africa
Richards Bay, South Africa
2 Sites, Bloemfontein, South Africa
Olifantsfontein, South Africa
Bellville - Cape Town, South Africa
Dundee, South Africa
Potchefstroom, South Africa
Reiger Park, South Africa
Brits, South Africa
Somerset West, South Africa
Hatfield - Pretoria, South Africa
2 Sites, Port Elizabeth, South Africa
Westdene - Bloemfontein, South Africa
Additional Information
Starting date: August 2003
Ending date: February 2004
Last updated: April 23, 2008
|